Clopidogrel Maintaining Dosage in Acute Coronary Syndrome After Drug Eluting Stent Implantation
Launched by SHENYANG NORTHERN HOSPITAL · Nov 24, 2006
Trial Information
Current as of April 29, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosed with ACS and planned pretreatment with 600mg loading dose of commercially available clopidogrel (Plavix).
- • between ages of 18 Years and above
- • Presence of one or several stenosis in native coronary arteries requiring PCI and suitable for DES implantation.
- • Willing and able to sign informed consent.
- Exclusion Criteria:
- • A history of bleeding diathesis.
- • New York Heart Association functional class IV.
- • Prior PCI or coronary bypass grafting \< 3 months.
- • contraindications to clopidogrel and aspirin (White blood cells counts \< 4×109/L or platelet counts \<100 g.l-1 ;creatinine clearance \<25 ml • min-1 ;active liver disease).
- • use of glycoprotein IIb/IIIa inhibitors before PCI.
About Shenyang Northern Hospital
Shenyang Northern Hospital is a leading healthcare institution based in Shenyang, China, renowned for its commitment to advancing medical research and patient care. As a clinical trial sponsor, the hospital focuses on innovative therapeutic solutions and strives to enhance treatment outcomes across various medical fields. With a dedicated team of experienced researchers and clinicians, Shenyang Northern Hospital emphasizes rigorous ethical standards and scientific integrity in its trials. The institution is equipped with state-of-the-art facilities and a diverse patient population, enabling it to contribute significantly to the global medical research community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Yaling Han, Dr
Principal Investigator
Shenyang Northern Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials